Диссертация (1174326), страница 25
Текст из файла (страница 25)
282–286.159. Mostello D., Kallogjeri D., Tungsiripat R., Leet T. Recurrence of preeclampsia:effects of gestational age at delivery of the first pregnancy, body mass index, paternity,and interval between births // Am J Obstet Gynecol. – 2008. - 199(1). – P. 55e1–55e7.151160. Mukherjee R. Morphometric evaluation of preeclamptic placenta using lightmicroscopic images // Biomed Res Int.
– 2014. – 29. – P. 36-40.161. Neiger R. Long-Term Effects of Pregnancy complications on Maternal Health: AReview // J Clin Med. – 2017. - 27. – P. 6-8.162. Norrby K., Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotesangiogenesis mediated by heparin-binding VEGF-A in vivo // APMIS. - 2010. - 118(12).– P. 949-957.163.
Odibo A.O., Goetzinger K.R., Odibo L., Tuuli M.G. Early prediction and aspirin forprevention of pre-eclampsia (EPAPP) study: a randomized controlled trial // UltrasoundObstet Gynecol. – 2015. – 8. – P. 37-40.164. Pallotto E.K., Kilbride H.W. Perinatal outcome and later implications of intrauterinegrowth restriction // Clin Obstet Gynecol. – 2006. - 49(2). – P. 257-269.165. Park F., Russo K., Williams P. Prediction and prevention of early-onset preeclampsia: impact of aspirin after first-trimester screening // Ultrasound Obstet Gynecol.– 2015.
– 17. – P. 215-225.166. Pratt A., Da Silva Costa F., Borg A.J. Placenta-derived angiogenic proteins and theircontribution to the pathogenesis of preeclampsia // Angiogenesis. – 2015. -18. – P. 115–23.167. Procopciuc L.M., Caracostea G., Zaharie G., Stamatian F. Maternal/newbornVEGF-C936T interaction and its influence on the risk, severity and prognosis ofpreeclampsia, as well as on the maternal angiogenic profile // J Matern Fetal NeonatalMed.
– 2014. - 27(17). – P. 1754-1760.168. Rana S., Karumanchi S.A., Levine R.J. et al. Sequential changes in antiangiogenicfactors in early pregnancy and risk of developing preeclampsia // Hypertension. – 2007.– 50. – P. 137-142.169. Ranheim T., Staff A.C., Henriksen T. VEGF mRNA is unaltered in decidual andplacental tissues in preeclampsia at delivery // Acta Obstet Gynecol Scand. – 2001. -80.– P. 93–98.152170. Raymond D., Peterson E. A critical review of early-onset and late-onsetpreeclampsia // Obstetrical and Gynecological Survey.
– 2011. - 66(8). – P. 497–506.171. Resta L., Capobianco C., Marzullo A., Piscitelli D., Sanguedolce F., Schena F.P.,Gesualdo L. Confocal laser scanning microscope study of terminal villi vessels innormal term and pre-eclamptic placentas // Placenta. – 2006. - 27(6-7). – P. 735-739.172. Rey, E., Garneau, P., David, M., Gauthier, R., Leduc, L., Michon, N., Morin, F.,Demers, C., Kahn, S.R., Magee, L.A.
& Rodger, M. Dalteparin for the prevention ofrecurrence of placental-mediated complications of pregnancy in women withoutthrombophilia: a pilot randomized controlled trial // Journal of Thrombosis andHaemostasis. – 2009. – 7. – P. 58–64.173. Roberge S., Villa P., Nicolaides K. Early administration of lowdose aspirin for theprevention of preterm and term preeclampsia: a systematic review and meta-analysis //Fetal Diagn Ther.
– 2012. – 31. – P. 141–146.174. Robert L.G., Elizabeth M.M. Maternal, fetal and neonatal mortality: lessons learnedfrom historical changes in high income countries and their potential application to lowincome countries // Matern Health, Neonatol Perinatol. – 2015. -1. – P. 3.175. Roberts D.J., Post M.D. The placenta in preeclampsia and intrauterine growthrestriction // J Clin Pathol. – 2008.
– 61. – P. 1254–1260.176. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D., Walker I.D.,Greaves M., Brenkel I., Regan L. & Greer I.A. Thrombophilia in pregnancy: a systematicreview // British Journal of Haematology. – 2006.
– 132. – P. 171–196.177. Robinson C.J., Johnson D.D., Chang E.Y. et al. Evaluation of placenta growth factorand soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia //Am J Obstet Gynec. – 2006. – 195. - P. 255-259.178. Robson S.C., Simpson H., Ball E., Lyall F., Bulmer J.N. Punch biopsy of the humanplacental bed // American Journal of Obstetrics and Gynecology. – 2002. -187(5). – P.1349–55.179. Rodger M.A., Walker M.C., Smith G.N., Wells P.S., Ramsay T., Langlois N.J.,Carson N., Carrier M., Rennicks White R., Shachkina S., Wen S.W. Is thrombophilia153associated with placenta-mediated pregnancy complications? A prospective cohort study// J Thromb Haemost.
– 2014. -12(4). – P. 469-78.180. Rodger M.A., Gris J.C., de Vries J.I.P., Martinelli I., Rey É., Schleussner E.,Middeldorp S., Kaaja R., Langlois N.J., Ramsay T., Mallick R., Bates S.M., AbheidenC.N.H, Perna A., Petroff D., de Jong P., van Hoorn M.E., Bezemer P.D., Mayhew A.D.Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications StudyGroup. Low-molecular-weight heparin and recurrent placenta-mediated pregnancycomplications: a meta-analysis of individual patient data from randomised controlledtrials // Lancet.
– 2016. – 26. - 388(10060). – P. 2629-2641.181. Rodger, M., Hague, W., Kingdom, J., Kahn, S., Karovitch, A., Sermer, M., Clement,A.M., Coat, S., Chan, W.S., Said, J., Rey, E., Robinson, S., Khurana, R., Demers, C.,Kovacs, M.J., Solymoss, S., Hinshaw, K., Dwyer, J., Smith, G., McDonald, S., NewsteadAngel, J., McLeod, A., Khandelwal, M., Silver, R.M., Le Gal, G., Greer, I., Keely, E.,Rosene-Montella, K., Walker, M., Wells, P.S. Antepartum dalteparin versus noantepartum alteparin for the prevention of pregnancy complications in pregnant womenwith thrombophilia (TIPPS): a multinational open label randomised trial // The Lancet. 2014. – 384 (9955).
– P. 1673-1683.182. Rosenberg V.A., Buhimschi I.A., Lockwood C.J., Paidas M.J., Dulay A.T., RammaW., Abdel-Razeq S.S., Zhao G., Ahmad S., Ahmed A., Buhimschi C.S. Heparin elevatescirculating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant womenreceiving anticoagulation therapy // Circulation. – 2011. - 124(23). – P. 2543-2553.183. Salimi S., Yaghmaei M., Tabatabaei E., Mokhtari M., Naghavi A. Vascularendothelial growth factor (VEGF) -634G\C polymorphism was associated with severepre-eclampsia and lower serum VEGF level // J Obstet Gynaecol Res.
– 2015. - 41 (12).– P. 1877-1883.184. Samantha E.P., Martha M.W. Epidemiology of ischemic placental disease: a focuson preterm gestations // Semin Perinatol. – 2014. – 38. – P. 133–138.185. Şamlı H. Vascular endothelial growth factor gene 1154 G/A, 2578 C/A, 460 C/T,936 C/T polymorphisms and association with recurrent pregnancy losses. GenetMolRes.– 2012.
- 11(4). - P. 4739-4745.154186. Sander C.M., Gilliland D., Richardson A., Foley K.M., Fredericks J. Stillbirths withplacental hemorrhagic endovasculitis: a morphologic assessment with clinicalimplications // Archives of Pathology and Laboratory Medicine. – 2005.
-129(5). – P.632–638.187. Sandrim V. C., Palei A. C., Cavalli R. C., Araújo F. M., Ramos E. S., Duarte G.,Tanus-Santos J. E. Vascular endothelial growth factor genotypes and haplotypes areassociated with pre-eclampsia but not with gestational hypertension // Molecular humanreproduction.
– 2009. - 15(2). – P. 115-120.188. Sankar K.D., Bhanu P.S., Ramalingam K., Kiran S., Ramakrishna B.A.Histomorphological and morphometrical changes of placental terminal villi ofnormotensive and preeclamptic mothers // Anat Cell Biol. – 2013. - 46(4). – P. 285-290.189. Sebire N.J. et al. Placental massive perivillous fibrin deposition associated withantiphospholipid antibody syndrome // Br J Obstet Gynaecol. – 2002. - 109 (5).
– P. 570–573.190. Sela S., Natanson-Yaron S., Zcharia E., Vlodavsky I., Yagel S., Keshet E. Localretention versus systemic release of soluble VEGF receptor-1 are mediated by heparinbinding and regulated by heparanase // Circ Res. – 2011. - 108(9). - P. 1063-1070.191. Seyam Y.S., Al-Mahmeid M.S., Al-Tamimi H.K. Umbilical artery Doppler flowvelocimetry in intrauterine growth restriction and its relation to perinatal outcome // Int.J. Gynecol. Obstet. – 2002. - 77 (2). – P. 131-137.192. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia // Lancet. – 2005. - 365(9461).– P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
